NCT06667583View on ClinicalTrials.gov

5p15/ 9q22/ 15q22 Hyperdiploidy and Their Significance in Multiple Myeloma Patients

Not yet recruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

January 1, 2026

Conditions
Multiple Myeloma, Neoplasms
All Listed Sponsors
lead

Assiut University

OTHER

NCT06667583 - 5p15/ 9q22/ 15q22 Hyperdiploidy and Their Significance in Multiple Myeloma Patients | Biotech Hunter | Biotech Hunter